Glyburide is a Small Molecule owned by Biogen, and is involved in 6 clinical trials, of which 4 were completed, and 2 are ongoing.

Glyburide (RP-1127) acts as a inhibitor of NCCa-ATP channels. Cation channel is regulated by intracellular calcium and adenosine triphosphate. The drug candidate has a neuroprotective effect on ischemic neurons and astrocytes through blocking upregulated NCCa-ATP channels. The channel is not constitutively expressed, but is transcriptionally upregulated in all cells of the neurovascular unit. It is activated by intracellular Ca2+ and blocked by intracellular ATP. When opened by depletion of intracellular ATP, this channel is responsible for complete depolarization due to massive Na+ influx, which creates an electrical gradient for Cl- and an osmotic gradient for H2O, resulting in cytotoxic edema and cell death.

The revenue for Glyburide is expected to reach a total of $677m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Glyburide NPV Report.

Glyburide is currently owned by Biogen.

Glyburide Overview

Glyburide (RP-1127) is under development for the treatment of brain edema (cerebral edema) following large hemispheric infarction (acute ischemic stroke) and traumatic brain injury (brain contusion). The drug candidate is administered intravenously. Glyburide acts on the sulfonylurea receptor 1 (Sur1)-regulated NCCa-ATP cation channel. The drug candidate is based on MPD technology.

The drug candidate was also under development for acute traumatic cervical spinal cord injury and acute subarachnoid hemorrhage.

Biogen Overview

Biogen is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson’s disease, CNS and neuromuscular disorders, Alzheimer’s disease, and idiopathic pulmonary fibrosis and stroke. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$10,981.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 18.3% over FY2020. In FY2021, the company’s operating margin was 25.9%, compared to an operating margin of 33.8% in FY2020. In FY2021, the company recorded a net margin of 14.2%, compared to a net margin of 29.8% in FY2020. The company reported revenues of US$2,508.5 million for the third quarter ended September 2022, a decrease of 3.1% over the previous quarter.

Quick View – Glyburide

Report Segments
  • Innovator
Drug Name
  • Glyburide
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.